Total 3, Current 1/1
Last December, the South Korean bio venture fund Aprogen Pharmaceuticals became Korea's 11th unicorn, according to tech market tracker CB Insights.
The firm that specialises in antibody engineering and recombinant protein engineering received US 16.7 million investment earlier in the year from venture capital firm Lindeman Asia Investment, helping take its valuation over US 1 billoion.
As little as five years ago, it was difficult for Korea's venture investors and the entrepreneurs they financed to see opportunities for exit. Initial Public offerings were as rare as unicorns, and the country's top conglomerates were M&A-shy.
Emerging companies lacked the deep pockets required for serious M&A activity as well.
That's all changed.
2019_KOREA INSTITUTE OF START-UP AND ENTREPRENEURSHIP DEVELOPMENT
04 President’s Message
06 Purpose of Establishment | Primary Tasks
07 History | Organization Structure
08 Business Structure | Achievements and Performance
10 Startup Education | Mentoring
12 Startup Commercialization
16 Startup Ecosystem
19 Events | Networking
21 Information SystemsCreated 2019/09/04 Hit 245 Download Detail